Gary Ulaner, MD, PhD

Dr. Gary Ulaner is the James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy (MIT) at the Hoag Family Cancer Institute and Professor of Radiology and Translational Genomics at the University of Southern California.

Gary has been the principal investigator of prospective clinical trials for six novel PET radiotracers for patients with breast cancer, prostate cancer and myeloma, funded by two National Institutes of Health R01s, as well as grants from the Department of Defense (DoD) Breast Cancer Research Programs, Susan G. Komen Foundation, and Rising Tide Foundation. His clinical trials emphasize targeted imaging to guide targeted therapy of cancer, particularly ER, HER2, PSMA and CD38 targeted PET imaging.

Gary in on the editorial board of 4 leading radiology journals, authored the text “Fundamentals of Oncologic PET/CT”, and is on the scientific advisory boards of ImaginAb, GE Healthcare, and the Lobular Breast Cancer Alliance.

Gary currently lives in Irvine, California, with his wife, Alena, son, Ilya, and daughter, Anabel. He met his wife swing dancing, and they are still dancing today, albeit with less frequency.

• National Institutes of Health Cancer Biology Pre-Doctoral Fellowship, 1994
• National Institutes of Health Medical Scientist Training Program, 1997
• National Institutes of Health Post-Doctoral Fellowship, 2001
• RSNA Roentgen Resident Research Award, 2005
• Resident of the Year, University of Southern California, 2009
• RSNA Excellence Award for Research, 2011
• Susan Komen for the Cure Career Catalyst Award, 2012
• Department of Defense Breakthrough Award, 2014
• Radiographics Educational Design Award, 2015
• Radiology Editor’s Recognition Award with Special Distinction, 2015
• Radiology Editor’s Recognition Award with Special Distinction, 2016
• Jon Shevell Young Scientist Scholarship, Susan Komen Foundation, 2016
• SNMMI Best Breast Cancer Research Abstract, 2016
• SNMMI first place prize in Basic Science, 2016
• MSKCC Department of Radiology, Excellence in Teaching Award, 2016
• Weill Cornell Department of Radiology, Best Teacher, 2016
• Jon Shevell Award from the Susan Komen Foundation, 2017
• Clinical Nuclear Medicine Editor’s Award, 2017
• Elected Fellow, American College of Nuclear Medicine, 2017
• First Hal O’Brien Rising Star Award, Society of Nuclear Medicine and Molecular Imaging (SNMMI), 2018
• American College of Nuclear Medicine – President’s Award, 2019
• James and Pamela Muzzy Endowed Chair, 2021

• Rutgers University, New Brunswick, NJ — BA — 05/1993 — Biology
• Stanford University School of Medicine, Stanford, CA — MD, PhD — 06/2000 — Cancer Biology
• Johns Hopkins , Baltimore, MD — 06/2001 — Internship
• University of Southern California, Los Angeles, CA — 06/2009 — Diagnostic Radiology
• University of Southern California, Los Angeles, CA — 06/2009 — Nuclear Medicine

• Molecular Pathogenesis and Therapy of Systemic Histiocytic Neoplasms
  NIH · R37CA259260 · Apr 1, 2021 – Mar 31, 2026 · Role: Co-Investigator
• Improved staging of lobular breast cancer with novel amino acid metabolic and tumor neovasculature receptor imaging.
  NIH · R21CA256280 · Dec 9, 2020 – Nov 30, 2022 · Role: Co-Investigator
• CD38-targeted immunoPET of myeloma: Phase 2 trial of clinical applications
  NIH · R01CA248398 · Jul 1, 2020 – Jan 31, 2024 · Role: Principal Investigator
• The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab
  NIH · R01CA204167 · Apr 1, 2016 – Mar 31, 2021 · Role: Co-Investigator

• Molecular Imaging and Therapy
• PET/CT
• Estrogen Receptor-targeted imaging
• PSMA-targeted imaging and therapy
• HER2-targeted imaging
• CD38-targeted imaging
• Translational Genomics

• What’s New in Cancer Care.
• Hoag Memorial Hospital Emerges as Southern California Leader in Molecular Imaging & Therapy Research & Care
• FDG-PET/CT shows promise for breast cancer patients younger than 40
• FDG-PET/CT shows promise for breast cancer patients younger than 40
• 18F-FDG PET-CT reveals 33% of previously undetected male breast cancer
• The Utility of FDG-PET in the Treatment of Hodgkin Lymphoma
• Hoag launches PET trials for prostate cancer, myeloma
• Hoag Memorial Hospital Makes Moves to Become National Leader In Molecular Imaging: Moving Closer to Precision Therapies
• Going to the molecular level to think big about cancer
• Hoag is first in the United States to offer the CD38-Targeted Immuno PET myeloma trial, funded by the National Institutes of Health

• Jadvar, Hossein
• Colletti, Patrick
• Conti, Peter
• Haiman, Christopher
• Lenz, Heinz-Josef
• Doroudinia, Abtin